MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

MDT

96.53

+0.95%↑

VEEV

287.9

+0.6%↑

A

138.07

-0.18%↓

HQY

93.65

+0.53%↑

PHR.US

22.97

+3.56%↑

Search

Roivant Sciences Ltd

Closed

SectorHealthcare

16.4 1.17

Overview

Share price change

24h

Current

Min

15.99

Max

16.77

Key metrics

By Trading Economics

Income

-22M

-274M

Sales

-5.4M

2.2M

Profit margin

-12,622.627

Employees

750

EBITDA

-284K

-284M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+25.29% upside

Market Stats

By TradingEconomics

Market Cap

3.4B

11B

Previous open

15.23

Previous close

16.4

News Sentiment

By Acuity

50%

50%

166 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 paź 2025, 22:33 UTC

Earnings

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 paź 2025, 22:21 UTC

Major Market Movers

Dentsply Sirona Shares Rise After SEC Probe Ends

14 paź 2025, 19:27 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 paź 2025, 17:56 UTC

Major Market Movers

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 paź 2025, 23:38 UTC

Market Talk

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 paź 2025, 22:12 UTC

Market Talk
Earnings

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 paź 2025, 21:40 UTC

Earnings

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 paź 2025, 21:39 UTC

Earnings

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 paź 2025, 21:38 UTC

Earnings

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 paź 2025, 21:06 UTC

Earnings

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 paź 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

14 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 paź 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

14 paź 2025, 20:50 UTC

Market Talk
Earnings

Health Care Roundup: Market Talk

14 paź 2025, 20:13 UTC

Earnings

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 paź 2025, 20:01 UTC

Earnings

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 paź 2025, 19:21 UTC

Market Talk
Earnings

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 paź 2025, 19:12 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 paź 2025, 19:08 UTC

Market Talk

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 paź 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 paź 2025, 18:59 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 paź 2025, 18:58 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 paź 2025, 18:58 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 paź 2025, 18:56 UTC

Acquisitions, Mergers, Takeovers

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 paź 2025, 18:46 UTC

Earnings

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 paź 2025, 18:04 UTC

Earnings

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 paź 2025, 18:01 UTC

Market Talk

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 paź 2025, 17:54 UTC

Earnings

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 paź 2025, 17:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 paź 2025, 17:50 UTC

Market Talk

Lower Dollar Provides Some Strength in Grains -- Market Talk

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

25.29% upside

12 Months Forecast

Average 20.31 USD  25.29%

High 24 USD

Low 16 USD

Based on 8 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

7

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

166 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat